WILLIAM BUCKNAM – Alcohol & Alcoholism Vol. 42, No. 2, pp. 158–160, 2007
Aims: To further test whether the baclofen-induced suppression of motivation to consume alcohol in animals could be transposed to humans.
Methods: A patient who had neither tolerated nor benefited from other alcohol treatment modalities was put on trial with baclofen on a dosage up to 140 mg/day.
Results: The patient reported dramatic reduction in cravings for and preoccupation with alcohol.
Conclusions: High-dose baclofen therapy was associated with complete and prolonged suppression of symptoms and consequences of alcohol-dependence.